[SW3] 共催企業ウェビナー3

[SW3-1] 四半世紀に及んだ腸管出血性大腸菌感染症の戦いと未来―感染症ミューズ細胞治療の挑戦―

藤井 潤¹，出澤 真理²，尾鶴 亮¹，若尾 昌平²，辻 高寛¹，松葉 隆司¹，黒沢 洋一³，大原 直也⁴，松本 壮吉⁵，安田 香央里⁶，飯野 守男⁷ (¹鳥取大学医学部医学科感染症学講座細菌学分野，²東北大学大学院医学系研究科細胞組織学分野，³鳥取大学医学部医学科社会医学講座健康政策医学分野，⁴岡山大学大学院医歯薬学総合研究科口腔微生物学分野，⁵新潟大学医学部細菌学教室，⁶株式会社セルイノベーター，⁷鳥取大学医学部医学科社会医学講座法医学分野)

In 1996, we experienced the largest outbreak of Enterohemorrhagic Escherichia coli (EHEC) O157 infection with contaminated school lunches. After this incident, we have been pursuing the question why people die from EHEC infection. In 1994, we had established a lethal mouse model which presented the central nervous system defects such as hindlimb paralysis with oral administration of EHEC O157. Another outbreak happened in 2011, of which reminded us how deadly the EHEC infection was. The contaminated food was raw beef as known as “Yukke”, that was associated with highly toxic EHEC O111. In the outbreak, 34 patients developed hemolytic uremic syndrome (HUS), 21 (62%) co-developed encephalopathy and five death occurred among them. This incident indicated us that the death in EHEC infection occurs due to encephalopathy. We used EHEC O111 oral inoculation mouse model to test Muse cell effect against the disease and successfully rescued mice from lethality in 2020. Muse cells not only inhibited cytokine storm, but also left no sequelae in mice that makes it attractive as a therapy for EHEC infection with high probability of developing long term sequalae after recovery from HUS and encephalopathy. Now, Muse cells are in several clinical trials testing the effects in inflammatory diseases such as cerebral infarction and myocardial infarction. We discovered that Muse cells are also capable of curing a bacterial infectious disease. Currently, the novel coronavirus infectious disease (COVID-19) is devastating the world, we have started Muse cell testing to a SARS-CoV-2 animal model that we hope our research moves this field forward to cure COVID-19 patients in the future.